ABT News & Events

Abbott announced it has secured CE Mark for the world's first dual glucose-ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, providing real-time visibility into both glucose levels needed for daily diabetes management as well as rising ketones that can lead to a diabetic ketoacidosis emergency. This marks the first time people with diabetes will be able to monitor ketones without traditional blood or urine tests. Abbott plans to begin launching Libre Duo systems in select European countries later this year.

Abbott announced that the American Cancer Society has released updated colorectal cancer screening guidelines that reaffirm Cologuard and Cologuard Plus as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC. Both tests are used at a three-year interval.